Advertisement vbandhakavi, Author at Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

AzurRx to acquire First Wave Bio for $229m

US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m. First Wave Bio is focussing on